Rosiglitazone, PPARgamma agonist (ab120762)
- Datasheet
- References (4)
Overview
-
Product name
Rosiglitazone, PPARgamma agonist -
Description
Selective PPARγ agonist -
Biological description
Selective PPARγ agonist (EC50 = 43 nM). Thiazolidinedione. Mediates adipocyte differentiation, increases lipogenesis and enhances fatty acid and glucose uptake. -
Purity
> 99% -
CAS Number
122320-73-4 -
Chemical structure
Properties
-
Chemical name
5-[[4- [2- (Methyl- 2- pyridinylamino) ethoxy] phenyl] methyl] - 2,4- thiazolidinedione -
Molecular weight
357.43 -
Molecular formula
C18H19N3O3S -
Storage instructions
Store at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
Solubility overview
Soluble in DMSO to 100 mM and in ethanol to 100 mM (with warming) -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
Source
Synthetic
-
Research areas
Associated products
-
Related Products
Applications
Our Abpromise guarantee covers the use of ab120762 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Functional Studies | Use at an assay dependent concentration. |
Images
-
Functional Studies - Rosiglitazone, PPARgamma agonist (ab120762)ab3580 staining glucocorticoid receptor in serum starved HeLa cells treated with rosiglitazone (120762), by ICC/IF. Changes in localization of glucocorticoid receptor (translocation from cytoplasm to nucleous) correlates with increased concentration of rosiglitazone, as described in literature.
The cells were incubated at 37°C for 1h in media containing different concentrations of ab120762 (rosiglitazone) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab3580 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
References
This product has been referenced in:
- Wang N et al. Role of peroxisome proliferator-activated receptor-? in atherosclerosis: an update. Circ J 75:528-35 (2011). Read more (PubMed: 21325726) »
- Chinetti G et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53-8 (2001). Read more (PubMed: 11135616) »
- Gouni-Berthold I et al. Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway. Naunyn Schmiedebergs Arch Pharmacol 363:215-21 (2001). Read more (PubMed: 11218074) »
- Forman BM et al. The peroxisome proliferator-activated receptors: ligands and activators. Ann N Y Acad Sci 804:266-75 (1996). Read more (PubMed: 8993549) »
